Skip to content

Biodesix Inc. (Nasdaq: BDSX) experienced 52% year-over-year core revenue growth for the second quarter of 2022, the company reported Friday.

The life sciences company reported $7.3 million in revenue from its core lung cancer diagnostic tests, up from $4.8 million in the second quarter of 2021. Biodesix brought in $11 million in revenue overall, down 8% year-over-year from $11.9 million.

The company attributed its overall sales decline to an expected decrease in COVID-19 testing revenue, which was down 51% to $3 million from $6.1 million a year ago.

Operating expenses were up 21%, to $18.6 million from $15.3 million.

Biodesix posted a net loss for the quarter of $15.8 million, 39% greater than the $11.3 million it lost in the second quarter of 2021. The company has $28.7 million in cash and equivalents on hand.

This article was first published by BizWest, an independent news organization, and is published under a license agreement. © 2022 BizWest Media LLC.

Join the Conversation

We invite you to use our commenting platform to engage in insightful conversations about issues in our community. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable to us, and to disclose any information necessary to satisfy the law, regulation, or government request. We might permanently block any user who abuses these conditions.